Ignite Creation Date:
2025-12-18 @ 4:15 AM
Ignite Modification Date:
2025-12-23 @ 6:57 PM
Study NCT ID:
NCT00764309
Status:
None
Last Update Posted:
2012-02-29 00:00:00
First Post:
2008-10-01 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
Sponsor:
None
Organization:
Study Overview
Official Title:
An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis
Status:
None
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: